Andreas Pasch
Overview
Explore the profile of Andreas Pasch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
2545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geroldinger-Simic M, Sohail A, Razazian M, Krennmayr B, Pernsteiner V, Putz T, et al.
Front Immunol
. 2024 Oct;
15:1425885.
PMID: 39399492
Background: Systemic sclerosis (SSc) is a complex auto-immune disease characterized by vascular damage, inflammation, fibrosis and calcinosis, where pulmonary involvement is the leading cause of mortality. Calciprotein particles (CPPs) are...
2.
Sohail A, Obereigner J, Mitter G, Schmid T, Hofer A, Schuster G, et al.
Clin Kidney J
. 2024 Sep;
17(9):sfae258.
PMID: 39286240
Background: The excessive cardiovascular mortality of patients with chronic kidney disease (CKD) could be linked to mineral stress, the biological consequence of calcium-phosphate nanoparticle exposure. This study investigated whether zinc...
3.
Feenstra L, Reijrink M, Pasch A, Smith E, Visser L, Bulthuis M, et al.
Cardiovasc Res
. 2024 Aug;
120(15):1953-1966.
PMID: 39102822
Aims: Calciprotein particles (CPPs) are circulating calcium and phosphate nanoparticles associated with the development of vascular calcification (VC) in chronic kidney disease (CKD). Although recent studies have been focusing on...
4.
Alesutan I, Razazian M, Luong T, Estepa M, Pitigala L, Henze L, et al.
Kidney Int
. 2024 Jul;
106(4):611-624.
PMID: 39084258
Medial vascular calcification in chronic kidney disease (CKD) involves pro-inflammatory pathways induced by hyperphosphatemia. Several interleukin 6 family members have been associated with pro-calcific effects in vascular smooth muscle cells...
5.
Thiem U, Lenz J, Haller M, Pasch A, Smith E, Cejka D
Clin Kidney J
. 2024 Jun;
17(6):sfae097.
PMID: 38919277
Background: This study investigated whether parathyroid hormone (PTH) lowering with etelcalcetide, and the consequent effects on mineral and bone metabolism, could improve serum calcification propensity (T50 time) and decrease calciprotein...
6.
Mencke R, Al Ali L, de Koning M, Pasch A, Minnion M, Feelisch M, et al.
Arterioscler Thromb Vasc Biol
. 2024 Jun;
44(8):1884-1894.
PMID: 38899469
Background: Vascular calcification is associated with increased mortality in patients with cardiovascular disease. Secondary calciprotein particles are believed to play a causal role in the pathophysiology of vascular calcification. The...
7.
Cejka D, Thiem U, Blinzler E, Machacek J, Voelkl J, Smith E, et al.
Kidney Int Rep
. 2024 Jun;
9(6):1765-1773.
PMID: 38899177
Introduction: Serum calcification propensity (T50 time) is associated with mortality in patients on dialysis. Several solitary interventions improve T50. However, whether a combination of interventions yields further increases in T50...
8.
Van der Vaart A, Eelderink C, Goor H, Hillebrands J, Te Velde-Keyzer C, Bakker S, et al.
J Intern Med
. 2024 Mar;
295(6):748-758.
PMID: 38528373
Background And Aims: Individuals with type 2 diabetes (T2D) have a higher risk of cardiovascular disease, compared with those without T2D. The serum T50 test captures the transformation time of...
9.
Leidner A, Cai X, Zelnick L, Lee J, Bansal N, Pasch A, et al.
Kidney Med
. 2023 Nov;
5(11):100723.
PMID: 37915961
Rationale & Objective: Heart failure (HF) is an important cause of morbidity and mortality among individuals with chronic kidney disease (CKD). A large body of evidence from preclinical and clinical...
10.
Egli-Spichtig D, Hamid A, Pastor Arroyo E, Ketteler M, Wiecek A, Rosenkranz A, et al.
Clin Kidney J
. 2023 Oct;
16(10):1622-1633.
PMID: 37779856
Background: Hyperphosphatemia is associated with increased mortality and cardiovascular morbidity of end-stage kidney failure (ESKF) patients. Managing serum phosphate in ESKF patients is challenging and mostly based on limiting intestinal...